27 Mar 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Pricing of Concurent Public Oferings of 2.50% Convertible Senior Notes Due 2032 and Comon Stock with Agregate Gros Proceds of $30.0 Milion Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
23 Mar 2026 by admin in UncategorizedComments Tempest Therapeutics Announces Up To $6 Million Private Placement
18 Mar 2026 by admin in UncategorizedComments Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
11 Mar 2026 by admin in UncategorizedComments Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
